Treatment satisfaction, disease severity and healthcare use in patients with axial spondyloarthritis in the United States and Europe

Further Publications Rheumatology

Rheumatologist and patient perspectives on axial spondyloarthritis management and treatment satisfaction in Europe

Semin Arthritis Rheum

Baraliakos X, Navarro-Compán V, Nikiphorou E, Pham T, Ciccia F, Truman I, Kranz B, Castellano G, Jus A, Durán MR, Lowe J, Ramiro S

doi: 10.1016/j.semarthrit.2025.152884

Further Publications Rheumatology

Almost half of the patients with axial spondyloarthritis reporting an acceptable symptom state have high disease activity; data from two standard-of-care cohorts

Semin Arthritis Rheum

Carbo M, Kampman A, Paap D, Wink F, Webers C, Vonkeman H, van Tubergen A, Arends S, Spoorenberg A

doi: 10.1016/j.semarthrit.2025.152903

Further Publications Rheumatology

An app-based nonpharmacological intervention improves patient-reported disease activity, functionality, and quality of life in patients with axial spondyloarthritis: a randomised controlled trial

Ann Rheum Dis

Strunz PP, Froehlich M, Heusinger T, le Maire M, Fleischer A, Luetkens KS, Possler P, Gernert M, Labinsky H, Gadeholt O, Leppich R, Schmieder A, Hammel L, Sperlich B, Einsele H, Schmalzing M

doi: 10.1016/j.ard.2026.02.016

Rheumatoid Arthritis

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Arthritis Care Res (Hoboken)

Xie F, Beukelman T, McCormick NP, Curtis JR

doi: 10.1002/acr.80010

Further Publications Rheumatology

Achieving inactive disease state in men and women with axial spondyloarthritis: results from a multi-country prospective observational study

Rheumatology (Oxford)

Poddubnyy D, Sieper J, Akar S, Muñoz-Fernández S, Haibel H, Protopopov M, Altmaier E, Ganz F, Inman RD

doi: 10.1093/rheumatology/keaf447

Rheumatoid Arthritis

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex

Arthritis Res Ther

Flouri ID, Repa A, Avgoustidis N, Pitsigavdaki S, Kalogiannaki E, Kalligianni-Sofikiti K, Emmanouilidou E, Marolachaki E, Bertsias G, Sidiropoulos P

doi: 10.1186/s13075-025-03664-y

Systemic Lupus Erythematosus

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

Rheumatology (Oxford)

Nakanishi E, Matsushita M, Minowa K, Tada K, Kawamoto T, Kusaoi M, Amano H, Kon T, Morimoto S, Ikeda K, Suzuki S, Nozawa K, Yang KS, Matsudaira R, Katagiri A, Tsushima H, Urasaki W, Nojiri S, Yamaji K, Tamura N

doi: 10.1093/rheumatology/keaf349

Psoriatic Arthritis

Comparison of radiographic spinal changes and their progression in patients with axial spondyloarthritis vs. psoriatic arthritis with inflammatory axial involvement

Arthritis Res Ther

Sewerin P, Redeker I, Lavda E, Supp G, Sieghart D, Aletaha D, Mandl P, Kiefer D, Baraliakos X

doi: 10.1186/s13075-025-03692-8

Psoriatic Arthritis

Access, Effectiveness, Safety And Survival Of Secukinumab In Patients With Axial Spondyloarthritis And Axial Psoriatic Arthritis: Real-Life Study In Argentina

J Rheumatol

Martire MV, Marin J, Maldonado Ficco H, Benegas M, Giorgis P, Vila D, Isnardi CA, Gamba MJ, Flores Trejo JF, Perez-Alamino R, Chemez AJ, Ferreyra Garrott L, Cosatti MA, Buschiazzo EA, Correa MLA, Aguila Maldonado R, Manases Roldan B, Lizarraga C, Alfaro MA, Morbiducci J, Ingolotti LV, Pendón G, Nieto RE, Velloso MS, Martinez Muñoz A, Lloves Schenone N, Zamora NV, Saturansky E, Costi AC, Haye Salinas MJ, Airoldi CA, Granel A

doi: 10.3899/jrheum.2024-1185

Related content

Rheumatologist and patient perspectives on axial spondyloarthritis management and treatment satisfaction in Europe

Almost half of the patients with axial spondyloarthritis reporting an acceptable symptom state have high disease activity; data from two standard-of-care cohorts

An app-based nonpharmacological intervention improves patient-reported disease activity, functionality, and quality of life in patients with axial spondyloarthritis: a randomised controlled trial

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Achieving inactive disease state in men and women with axial spondyloarthritis: results from a multi-country prospective observational study

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

Comparison of radiographic spinal changes and their progression in patients with axial spondyloarthritis vs. psoriatic arthritis with inflammatory axial involvement

Access, Effectiveness, Safety And Survival Of Secukinumab In Patients With Axial Spondyloarthritis And Axial Psoriatic Arthritis: Real-Life Study In Argentina